Objectives: Postherpetic Neuralgia (PHN) is a painful condition that can last for months or years, mostly affecting the elderly. Commonly recommended first-line medications include topical lidocaine, antidepressants, and anticonvulsants, but other CNS depressants, including opioids, are frequently utilized. To investigate PHN treatment patterns, we conducted a retrospective analysis using a large, de-identified US electronic health record database (Health Facts®, Cerner Corp., Kansas City, MO, USA).
Methods:
Patients receiving PHN treatment between January 2000 and March 2015 were identified by an established algorithm modified to include patients with an ICD-9 diagnosis code for herpes zoster, who were prescribed a lidocaine patch in the same visit. A univariate analysis of the population was used to investigate the prescribed PHN treatments. Propensity-score based, matched patient subpopulations were used to quantitatively examine medication dosing, complications, and other outcomes.
Results: Opioids were the most frequent analgesics prescribed (35% of patients) and were also frequently used as a first-line medication. In contrast, agents with less systemic adverse effects, such as topical lidocaine, were commonly used as second-line therapies and in older and more severely ill patients. Analgesic polypharmacy was prevalent in PHN patients, with 85% receiving more than one analgesic and 20% receiving more than five analgesics within a 60-day window.
Conclusions: Despite published evidence that first-line treatments should include topical lidocaine, antidepressants, and anticonvulsants, our analyses revealed that PHN management is associated with considerable levels of opioid use. Patients receiving both opioids and topical lidocaine received more total opioids, suggesting they are not tapered following addition of analgesics. Although opioids are commonly considered or recommended as either second-or third-line by PHN-treating physicians, they appear to be a first-line PHN treatment in real world practice. [1] [2] [3] This lack of adherence to clinical practice guidelines may unnecessarily put PHN patients at risk and demonstrates a need for further education and awareness.
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Postherpetic neuralgia (PHN) is the most frequent complication of herpes zoster (HZ) reactivation and occurs in approximately 20% of shingles patients. 1,3 Peripheral nerve damage due to the HZ infection is the underlying cause of PHN, and the resulting nerve pain can persist for months to years. [1] [2] [3] Because the vast majority of shingles patients are over 65 years old, PHN disproportionately affects an elderly population that may already display significant comorbidities or be receiving multiple pharmacologic treatments. [1] [2] [3] Treatment for PHN is multimodal, and first-line therapies include gabapentinoids, lidocaine 5% patches, and (off-label) tricyclic antidepressants. 1, 2, 4 Opioid medications are commonly considered or recommended as second-or thirdline treatments for PHN by physicians, and NSAIDs are not recommended/considered ineffective for PHN. 1-3 Topical capsaicin is also used as a second-or third-line therapy. 1, 3 The topical treatments for PHN, including lidocaine 5% patches and capsaicin, have relatively benign safety profiles, with most adverse events limited to the site of application. 5, 6 In contrast, each of the systemic treatments for PHN are associated with a number of adverse events. Gabapentinoids, including gabapentin and pregabalin exhibit dose dependent effects, including sedation, dizziness, ataxia, and visual disturbances. 4, 7 Opioid use can lead to constipation, sedation, and nausea, among other adverse events, and can lead to opioid use disorders. 8 In addition to having limited effect in PHN, NSAIDs are associated with gastrointestinal complications (ulcers, perforation, and bleeding), renal dysfunction, and cardiovascular adverse effects. 9 Although multimodal therapy is the standard for treatment of PHN, the increased susceptibility of elderly PHN patients to adverse events and the potential polypharmacy environment of these patients suggests that PHN treatments should be carefully and rationally constructed according to evidencebased guidelines.
• Evidence-based PHN treatment protocols commonly recommend opioid medication as second-or third-line treatments, but opioids are most often prescribed as part of a first line therapy
• Although NSAIDs are considered ineffective in PHN treatment, a significant fraction of patients still receive these medications
• Lidocaine 5% patches, a recommended first-line treatment with a favorable safety profile, are instead used as second-or third-line treatment
• PHN patients exhibit a number of comorbidities that could influence the selection of PHN therapies
• Lidocaine 5% patch patients are more likely to be older and have an increased frequency of comorbidities
• Although PHN treatment typically requires multimodal treatment, patients are exposed to a high degree of polypharmacy (≥4 medications) that may contribute to adverse effects • A retrospective cohort of patients was assembled from Cerner HealthFacts ® , an electronic database of aggregated, de-identified clinical and administrative data from 614 US hospitals and health systems
• The database includes comprehensive clinical, pharmacy, laboratory, registration, and billing data from all participating patient care locations, including date and time stamped admissions, discharges, medication orders, clinical events, laboratory orders, specimen collections, and laboratory results
• PHN patients were selected based on ICD-9 coding and treatment timing, using the protocol established by Klompas et al 10
• Two or more visits with an ICD-9 for herpes zoster 21 days or more apart AND a new prescription for an analgesic, antidepressant, or anticonvulsant
• An ICD-9 code for herpes zoster with nervous system complications (053.19)
• ICD-9 for neuralgia within 180 days of a visit for herpes zoster
• Additional PHN patients were captured by selecting for patients with ICD-9 for 053.XX (herpes zoster) and a prescription for a 5% lidocaine patch in the same visit A) The top ten Exlihauser comorbidities 11 associated with the PHN patient population. B) The ages of patients receiving lidocaine 5% patches and treatment regimens without lidocaine 5% patches were assessed. C) Unmatched populations of patients receiving lidocaine 5% patches and treatment regimens without lidocaine 5% patches were examined for the frequency of diagnosis coding for the Elixhauser comorbidities. The 15 comorbidities with the greatest difference between the two populations are presented. 
Analysis and Statistics
• To determine the treatment landscape of the PHN cohort, a univariate description was utilized
• Quantitative analyses of treatment dosing and associated outcomes was conducted using propensity score matched populations. Patients were matched 1:1 on their propensity score and the success of matching was assessed using standardized differences methods, chi-square tests for the categorical variables, and t-tests for continuous variables
• Propensity scores were developed via logistic regression based on patient demographics, hospital characteristics (i.e. size, region, teaching status, etc.), and comorbidities
